#fdanews

🚨 SNACK RECALL ALERT (USA) 🚨

Frito-Lay has issued a recall for Miss Vickie’s Spicy Dill Pickle Chips after discovering some bags may contain undeclared milk — a potentially life-threatening allergen for people with dairy allergies.

The recalled chips were sold in 6 U.S. states including Texas, Oklahoma, and Louisiana.

⚠️ Check your pantry immediately if you bought this product.

👉 Full recall details here https://maalfreekaa.blogspot.com/2026/03/frito-lay-miss-vickies-chips-recall-milk-allergen.html

(Source – CNBC)

Revolutionary Therapy Offers New Hope for Small-Cell Lung Cancer Patients

In a monumental stride towards combating cancer, the Food and Drug Administration (FDA) has greenlit Amgen’s ground-breaking therapy, Imdelltra, for individuals grappling with the deadliest variant of lung cancer. This approval signifies a pivotal moment in the battle against advanced small-cell lung cancer, ushering in a glimmer of optimism for those confronted with this formidable diagnosis.

Imdelltra: A Beacon of Optimism

Formerly known as tarlatamab, Amgen’s Imdelltra has received the FDA’s nod as a subsequent or advanced line of treatment for patients contending with advanced small-cell lung cancer. This pivotal milestone enables patients to access the therapy when conventional treatments, such as chemotherapy, fail to halt disease progression. Encouraging clinical trials have illuminated the potential of Imdelltra, showcasing its ability to curb tumor growth and significantly prolong patients’ survival rates.

Confronting a Devastating Illness

Small-cell lung cancer, constituting roughly 15% of lung cancer cases worldwide, presents a formidable challenge due to its aggressive demeanor and rapid dissemination throughout the body. Manifesting symptoms like hemoptysis, persistent coughing, thoracic discomfort, and dyspnea, the illness bestows a dire prognosis, with only a scant 3% of patients surviving beyond a five-year mark. Against this stark backdrop, Amgen’s Imdelltra emerges as a beacon of hope, offering tangible benefits for patients like Lynne Bell.

Personal Narratives: Tales of Tenacity

Lynne Bell, a warrior battling small-cell lung cancer, shares her journey of resilience and hope subsequent to undergoing treatment with Imdelltra. Despite grappling with initial despair post-diagnosis, Lynne’s participation in a clinical trial involving Imdelltra has yielded astounding outcomes, including marked tumor regression and ameliorated overall well-being. Similarly, Maida Mangiameli, a staunch advocate and survivor of cancer, underscores the significance of pioneering therapies like Imdelltra in instilling renewed hope for individuals grappling with the disease.

Charting the Path Forward: Bright Horizons and Ongoing Investigations

FDAnews Announces: Top 7 Keys to eMDR Success: The Deadline is Near, Are You Ready? Webinar, March 31, 2015

Falls Church, VA (PRWEB) March 13, 2015

Top 7 Keys to eMDR Success: The Deadline is Near, Are You Ready? **FDAnews Webinar** March 31, 2015 — 1:30 p.m. – 3:00 p.m. EDT http://www.fdanews.com/KeyseMDRSuccess

The deadline looms.

Devicemakers must take steps now to secure a production account for submitting electronic Medical Device Reports (eMDRs), ahead of an Aug. 14, 2015 deadline for…

New Post has been published on http://crynew.com/medicine/fdanews-announces-introductory-offer-for-international-devices-diagnostics-monitor-subscription/

FDAnews Announces: Introductory Offer for International Devices & Diagnostics Monitor Subscription

Falls Church, VA (PRWEB) January 15, 2015

International Devices & Diagnostics Monitor **FDAnews Newsletter** http://www.fdanews.com/IDDMnew

International Devices & Diagnostics Monitor (IDDM) is a one-stop resource that brings devicemakers a complete, global picture of the medical device regulations that affect their business.

Nowhere else will readers find a more comprehensive collection of the regulatory changes in the US, EU, Asia, Latin America, the Middle East, Australia and the rest of the world.

The subscription includes a weekly newsletter to keep readers up to date with global regulations as changes happen, including complete text of all government documents.

In addition, subscribers will also receive a quarterly update with expert analysis on key device and diagnostic issues from around the world. Most importantly, they will have access to a website completely dedicated to global medical device regulations, http://www.IDDMonitor.com.

With International Devices & Diagnostics Monitor, subscribers won’t miss a thing. They will be fully prepared with an unmatched source of critical information and news, including:

    24/7 access to updates important regulatory news facing manufacturers of devices and diagnostics around the globe     Continuous monitoring of FDA, EU, IMDRF and Asian regulators as they revise requirements for clinical submissions, approvals, postmarket monitoring, reimbursement and inspections     A one-stop resource center for up-to-the-minute medical device and diagnostics regulatory information and government documents     Expert analysis and interviews with top regulators regarding key changes emerging in countries around the world

Could devicemakers track these global changes themselves? Perhaps – at the cost of countless hours. Why even try? FDAnews is doing the job, at a fraction of what it would cost to do it in-house.

So don’t waste another instant. Start a no-risk subscription to IDDM today.

Publication Details: International Devices & Diagnostics Monitor **FDAnews Newsletter** http://www.fdanews.com/IDDMnew

1-Year Subscription: Special Introductory Offer $ 947; Regular Price: $ 1,247

Easy Ways to Order: Online:     http://www.fdanews.com/IDDMnew By phone: 888-838-5578 or 703-538-7600

100% Money-Back Guarantee: Our ironclad guarantee ensures your satisfaction. If at any time during your one-year subscription you become dissatisfied, cancel and receive a full refund. No questions asked.

About FDAnews: FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations.